# A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Source: https://onco.cc/trials/nct07287995/  
OnCo record `nct07287995` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Enfortumab vedotin and Carboplatin in advanced solid tumours, run by Astellas Pharma Global Development, Inc., now recruiting.

## Summary

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors is a phase 1/2 interventional study registered as NCT07287995 by Astellas Pharma Global Development, Inc., with 428 participants planned, started 2026-02-05 and due to reach its primary completion in 2029-06-30. Interventions recorded: ASP2998, Pembrolizumab, Enfortumab Vedotin and Carboplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07287995
- Phase: 1/2
- Setting: A Phase 1b/2 Study of ASP2998 as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors
- Sponsor: Astellas Pharma Global Development, Inc.
- Enrolled: 428

## Sources

- ClinicalTrials.gov NCT07287995: https://clinicaltrials.gov/study/NCT07287995

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Astellas](https://onco.cc/companies/astellas/)

---
JSON: https://onco.cc/api/v1/entities/nct07287995.json